Quercetin PK/PD Study in Healthy Adults and Patients With Hypercoagulable States

Phase 0 Completed 38 enrolled Beth Israel Deaconess Medical Center

Non-randomizedParallel-groupOpen-labelBasic science

Summary

The goal of this study is to evaluate how much quercetin or isoquercetin is absorbed after a single dose and evaluate for pharmacokinetic inhibition of protein disulfide isomerase. Pharmacodynamic studies will also be performed in an additional cohort of 10 patients with evidence of antiphospholipid antibodies

Timeline

Start: 2012-05
Primary completion: 2019-12
Completion: 2019-12

Publications

Stopa JD, Neuberg D, Puligandla M, Furie B, Flaumenhaft R, Zwicker JI. Protein disulfide isomerase inhibition blocks thrombin generation in humans by interfering with platelet factor V activation. JCI Insight. 2017 Jan 12;2(1):e89373. doi: 10.1172/jci.insight.89373.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Isoquercetin	Small molecule	500 mg	Oral
Subject	Isoquercetin	Small molecule	1000 mg	Oral
Subject	Quercetin	Small molecule	500 mg	Oral

Indications

No indication recorded.